科美诊断2025年度归母净利润4440.76万元 同比下降65.05%

Core Insights - The company reported a significant decline in both revenue and net profit for the fiscal year 2025, with revenue at 332.68 million yuan, down 23.75% year-on-year, and net profit attributable to shareholders at 44.41 million yuan, down 65.05% year-on-year [1] Group 1: Financial Performance - The company's operating revenue for the reporting period was 332.68 million yuan, reflecting a year-on-year decrease of 23.75% [1] - The net profit attributable to the parent company's shareholders was 44.41 million yuan, which represents a year-on-year decline of 65.05% [1] Group 2: Factors Affecting Performance - The primary reason for the decline in operating performance was the deep implementation of centralized procurement in the in vitro diagnostic industry, which pressured the prices of the company's main products, leading to a decrease in main business revenue [1] - The company maintained a high level of research and development investment to enhance its core competitiveness [1] - There was a reduction in government subsidies and other non-recurring profit and loss items compared to the same period last year [1]